Antisense composition and method for treating cancer

Details Antisense composition and method for treating cancer Antisense composition and method for treating cancer

2008-07-22

2008-07-22

Vivlemore, Tracy (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S024500

Reexamination Certificate

active

07402574

ABSTRACT:
A method and composition for treating colorectal cancer is disclosed. The method involves administering to a subject, a therapeutically effective amount of a morpholino antisense compound (i) having a nuclease-resistant backbone, (ii) capable of uptake by target cancer cells in the subject, (iii) containing between 10-40 nucleotide bases, and (iv) having a base sequence effective to hybridize to a region of processed or preprocessed human SNAIL RNA transcript.

REFERENCES:
patent: 5185444 (1993-02-01), Summerton
patent: 6060456 (2000-05-01), Arnold et al.
patent: 6133246 (2000-10-01), McKay et al.
patent: 6228579 (2001-05-01), Zyskind et al.
patent: 6239265 (2001-05-01), Cook
patent: 6495663 (2002-12-01), Rothbard et al.
patent: 6677153 (2004-01-01), Iversen
patent: 6784291 (2004-08-01), Iversen et al.
patent: 6828105 (2004-12-01), Stein et al.
patent: 6841542 (2005-01-01), Bartelmez
patent: 7049431 (2006-05-01), Iversen et al.
patent: 7094765 (2006-08-01), Iversen et al.
patent: 2003/0171335 (2003-09-01), Stein et al.
patent: 2004/0006030 (2004-01-01), Monia et al.
Agrawal et al.,“Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides.”Proc Natl Acad Sci U S A, 87(4):1401-5 (1990).
Barker et al.,Trends Mol. Med., 7(12):535-537 (2001).
Batlle,Nat Cell. Biol., 2(2):84-89. (1998).
Bennett, M.R. and Schwartz, S.M.,Circulation, 92(7):1981-1993 (1995).
Birchmeier and Behrens,Biochim Biophys ACTA, 1198(1):11-26.
Blanco et al., Oncongene, 21(20):3241-3246 (2002).
Bloomers et al.,Nucleic Acids Research, 22(20):4187-4194 (1994).
Bonham et al., “An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers.”Nucleic Acids Res23(7):1197-203 (1995).
Boudvillain et al., “Transplatin-modified oligo(2′-O-methyl ribonucleotide)s: a new tool for selective modulation of gene expression.”Biochemistry, 36(10): 2925-31 (1997).
Bussemakers et al.,Biochem. Biophys. Res. Commun., 203(2):1284-1290 (1994).
Cano et al.,Nat. Cell. Biol3., 2(2):76-83 (2000).
Carver et al.,Mol. Cell. Biol, 21(23):8184-8188 (1994).
Cavallaro et al.,Cancer Letters, 176(2):123-128 (2002).
Corpet et al.,Cancer Epidemiol. Biomarkers Prev, 12(5):391-400 (2003).
Dagle et al., “Targeted elimination of zygotic messages inXenopus laevisembryos by modified oligonucleotides possessing terminal cationic linkages”,Nucleic Acids Res., 28(10):2153-7 (2000).
Ding, D., et al.,Nucleic Acids Res., 24(2):354-60 (1996).
Fearon et al.,Cancer Cell., 3(4):307-310 (2003).
Felgner et al.,PNAS, 84(21): 7413-7 (1987).
Gait et al.,J. Chem. Soc., 0(14):1684-1686 (1974).
Gee, J. E., et al.,Antisense Nucleic Acid Drug Dev., 8(2):103-11 (1998).
Giroldi et al.,Biochem. Biophys. Res. Commun., 241(2):453-458 (1997).
Grille et al.,Cancer Res., 63(9):2172-2178 (2003).
Hajra et al.,Cancer Res., 62(6):1613-1618 (2002).
Hemavathy et al.,Gene, 257(1):1-12 (2000).
Hirohashi S.,Am. J. Pathology, 153(2):333-339 (1998).
Hudziak et al.,Antisnese&Nucleic Acid Drug Dev., 10(3):163-176 (2000).
Jiao et al.,Br. J. Cancer, 86(1):98-101 (2002).
Kinzler et al.,Cell, 87(2):159-170 (1996).
Kishimoto et al.,Gut, 47(6):812-819 (2000).
Lappalainen et al.,Biochim Biophys ACTA, 1196(2):201-208 (1994).
Lesnikowski et al., “Octa(thymidine methanephosphonates) of partially defined stereochemistry: synthesis and effect of chirality at phosphorus on binding to pentadecadeoxyriboadenylic acid.”Nucleic Acids Res., 18(8): 2109-15 (1990).
Llorens et al.,Lab Invest., 78(9):1131-1142 (1998).
Lou et al.,J. Biomaterials Appl., 15(4):307-320 (2001).
Mertes, M. P. and E. A. Coats (1969). “Synthesis of carbonate analogs of dinucleosides. 3′-Thymidinyl 5′-thymidinyl carbonate, 3′-thymidinyl carbonate.”J Med Chem., 12(1): 154-7.
Moser et al.,Science, 247(4940):322-324 (1990).
Nieto et al.,Nat. Rev. Mol. Cell Biol., 3(3):155-166 (2002).
Nyormoi, O. and Bar-Eli, M.,Clin Exp Metastasis, 20(3):251-63 (2003).
Perez-Losada et al.,Oncogene, 22(27):4205-11 (2003).
Perl et al.,Nature, 392(6672):190-3 (1998).
Poser et al.,J Biol Chem, 276(27):24661-6 (2001).
Rodrigo et al.,Exp. Cell Res., 248(2):358-371 (1999).
Rosivatz et al.,Am. J. Pathol., 161(5):1881-1891 (2002).
Roy et al.,Carcinogenesis, 23(1): 201-5 (2002).
Saito et al.,Am J Pathol., 159(6): 2117-24 (2001).
Sharov et al.,J Invest Dermatol., 120(1): 27-35 (2003).
Stein, D., et al.,Antisense Nucleic Acid Drug Dev., 7(3):151-7 (1997).
Takeichi et al.,Curr Opin. Cell Biol.,, 5(5):806-811 (1993).
Tan et al.,Oncogene, 20(1):133-140 (2001).
Toulme, J. J., R. L. Tinevez, et al. (1996). “Targeting RNA structures by antisense oligonucleotides.”Biochimie, 78(7):663-73.
Wali et al.,Cancer Epidemiol. Biomarkers Prev., 11(12):1653-1662 (2002).
Williams et al.,Br. J. Rheumatology, 35(8):719-724 (1996).
Yanez-Mo et al.,N. England J. Med., 348(5):403-413(2003).
Yokoyama et al.,Oral Oncology, 37(1):65-71 (2001).
Young et al.,Embo J., 22(21):5723-5733 (2003).
Roy et al.,Digestive Diseases and Sciences, 50(1):42-46 (2005).

Affiliated with

Also associated with

Rating

Antisense composition and method for treating cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antisense composition and method for treating cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense composition and method for treating cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2789038